Yıl 2017,
Cilt: 3 Sayı: 1, 23 - 24, 01.01.2017
Kaynakça
- 1. Ayaz S. Letter to editor: FDG-PET/CT evaluation of breast cancer. Ulutas Med J 2016; 2: 157−8.
- 2. Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 2015; 42: 328–54.
- 3. Delbeke D, Coleman RE, Guiberteau MJ, Brown ML, Royal HD,Siegel BA, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med 2006; 47: 885−95.
- 4. Glazer ES, Beaty K, Abdalla EK, Vauthey JN, Curley SA. Effectiveness of positron emission tomography for predicting chemotherapy response in colorectal cancer liver metastases. Arch Surg 2010; 145: 340−5.
- 5. De Iaco P, Musto A, Orazi L, Zamagni C, Rosati M, Allegri V, et al. FDG-PET/CT in advanced ovarian cancer staging: value and pitfalls in detecting lesions in different abdominal and pelvic quadrants compared with laparoscopy. Eur J Radiol 2011; 80: e98−103.
- 6. Mani N, George MM, Nash L, Anwar B, Homer JJ. Role of 18-Fludeoxyglucose positron emission tomographycomputed tomography and subsequent panendoscopy in head and neck squamous cell carcinoma of unknown primary. Laryngoscope 2016; 126: 1354−8.
- 7. Noble F, Bailey D; SWCIS Upper Gastrointestinal Tumour Panel, Tung K, Byrne JP. Impact of integrated PET/CT in the staging of oesophageal cancer: a UK population-based cohort study. Clin Radiol 2009; 64: 699−705.
- 8. Wu HB, Wang L, Wang QS, Han YJ, Li HS, Zhou WL, et al. Adenocarcinoma with BAC features presented as the nonsolid nodule is prone to be false-negative on 18F-FDG PET/CT. Biomed Res Int 2015; 2015: 243681.
- 9. Aquino SL, Halpern EF, Kuester LB, Fischman AJ. FDG-PET and CT features of non-small cell lung cancer based on tumor type. Int J Mol Med 2007; 19: 495−9.
- 10. Dammacco F, Rubini G, Ferrari C, Vacca A, Racanelli V. ¹⁸F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders. Clin Exp Med 2015; 15: 1−18.
- 11. Huyge V, Garcia C, Vanderstappen A, Alexiou J, Gil T, Flamen P. Progressive osteoblastic bone metastases in breast cancer negative on FDG-PET. Clin Nucl Med 2009; 34: 417−20.
Yıl 2017,
Cilt: 3 Sayı: 1, 23 - 24, 01.01.2017
Kaynakça
- 1. Ayaz S. Letter to editor: FDG-PET/CT evaluation of breast cancer. Ulutas Med J 2016; 2: 157−8.
- 2. Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 2015; 42: 328–54.
- 3. Delbeke D, Coleman RE, Guiberteau MJ, Brown ML, Royal HD,Siegel BA, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med 2006; 47: 885−95.
- 4. Glazer ES, Beaty K, Abdalla EK, Vauthey JN, Curley SA. Effectiveness of positron emission tomography for predicting chemotherapy response in colorectal cancer liver metastases. Arch Surg 2010; 145: 340−5.
- 5. De Iaco P, Musto A, Orazi L, Zamagni C, Rosati M, Allegri V, et al. FDG-PET/CT in advanced ovarian cancer staging: value and pitfalls in detecting lesions in different abdominal and pelvic quadrants compared with laparoscopy. Eur J Radiol 2011; 80: e98−103.
- 6. Mani N, George MM, Nash L, Anwar B, Homer JJ. Role of 18-Fludeoxyglucose positron emission tomographycomputed tomography and subsequent panendoscopy in head and neck squamous cell carcinoma of unknown primary. Laryngoscope 2016; 126: 1354−8.
- 7. Noble F, Bailey D; SWCIS Upper Gastrointestinal Tumour Panel, Tung K, Byrne JP. Impact of integrated PET/CT in the staging of oesophageal cancer: a UK population-based cohort study. Clin Radiol 2009; 64: 699−705.
- 8. Wu HB, Wang L, Wang QS, Han YJ, Li HS, Zhou WL, et al. Adenocarcinoma with BAC features presented as the nonsolid nodule is prone to be false-negative on 18F-FDG PET/CT. Biomed Res Int 2015; 2015: 243681.
- 9. Aquino SL, Halpern EF, Kuester LB, Fischman AJ. FDG-PET and CT features of non-small cell lung cancer based on tumor type. Int J Mol Med 2007; 19: 495−9.
- 10. Dammacco F, Rubini G, Ferrari C, Vacca A, Racanelli V. ¹⁸F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders. Clin Exp Med 2015; 15: 1−18.
- 11. Huyge V, Garcia C, Vanderstappen A, Alexiou J, Gil T, Flamen P. Progressive osteoblastic bone metastases in breast cancer negative on FDG-PET. Clin Nucl Med 2009; 34: 417−20.
Toplam 11 adet kaynakça vardır.
Ayrıntılar
| Birincil Dil | İngilizce |
|---|---|
| Bölüm | Editorial |
| Yazarlar | |
| Yayımlanma Tarihi | 1 Ocak 2017 |
| Yayımlandığı Sayı | Yıl 2017 Cilt: 3 Sayı: 1 |